Pembrolizumab + Lenvatinib
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Trial Timeline
Feb 12, 2019 → Oct 28, 2024
NCT ID
NCT03797326About Pembrolizumab + Lenvatinib
Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Eisai for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03797326. Target conditions include Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05308901 | Phase 2 | Active |
| NCT05064280 | Phase 2 | Recruiting |
| NCT04704219 | Phase 2 | Completed |
| NCT03797326 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors